NASDAQ:GNVC GenVec (GNVC) Stock Price, News & Analysis → Are you prepared for a Chinese 'invasion?' (From Behind the Markets) (Ad) Free GNVC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$7.19▼$7.1950-Day Range N/A52-Week Range$2.70▼$10.44VolumeN/AAverage Volume259,136 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get GenVec alerts: Email Address Ad Behind the MarketsWill this AI Micro-Cap be Bigger than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout AI stock. But right now... There's only ONE AI stock you should be watching.Get the full story here >>> About GenVec Stock (NASDAQ:GNVC)GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.Read More Ad Behind the MarketsWill this AI Micro-Cap be Bigger than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout AI stock. But right now... There's only ONE AI stock you should be watching.Get the full story here >>> GNVC Stock News HeadlinesDecember 18, 2023 | dailymail.co.ukCold virus can hunt down cancerNovember 7, 2023 | morningstar.comHuangshan Novel Co Ltd Class A 002014March 28, 2023 | finanznachrichten.deMaxCyte, Inc: MaxCyte Appoints Douglas Swirsky as Chief Financial OfficerFebruary 20, 2023 | thestreet.comGenVec Stock Hit by Pancreas Study's DetailsJanuary 3, 2023 | thestreet.comEarly Volume Plays: Novavax, GenVecDecember 18, 2022 | thestreet.comGenVec Value Slammed on Drug FailureSee More Headlines Receive GNVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GenVec and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2016Today6/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:GNVC CUSIPN/A CIK934473 Webwww.genvec.com Phone+1-240-6320740FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesWayne T. Hockmeyer Ph.D.Independence Chairman of the BoardDouglas J. SwirskyPresident, Chief Executive Officer, Corporate Secretary, DirectorWilliam N. Kelley M.D.Independent DirectorStefan D. Loren Ph.D.Independent DirectorQuinterol J. Mallette M.D.Independent DirectorMichael S. RichmanIndependent DirectorMarc R. SchneebaumIndependent DirectorMore Executives GNVC Stock Analysis - Frequently Asked Questions How were GenVec's earnings last quarter? GenVec Inc (NASDAQ:GNVC) released its earnings results on Friday, November, 4th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03. The biopharmaceutical company earned $0.17 million during the quarter, compared to analysts' expectations of $0.07 million. When did GenVec's stock split? GenVec's stock reverse split on Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of GenVec own? Based on aggregate information from My MarketBeat watchlists, some companies that other GenVec investors own include Sarepta Therapeutics (SRPT), Alibaba Group (BABA), NVE (NVEC), Microbot Medical (MBOT), Pluristem Therapeutics (PSTI), Acer Therapeutics (ACER), Chesapeake Energy (CHKAQ), MicroVision (MVIS) and Stone Energy (SGY). This page (NASDAQ:GNVC) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GenVec Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share GenVec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.